Get the Stockscreener App
0.5635
0.32%
0.0018
After Hours:
.59
0.0265
+4.70%
Reviva Pharmaceuticals Holdings Inc stock is traded at $0.5635, with a volume of 804.92K.
It is up +0.32% in the last 24 hours and down -55.98% over the past month.
See More
Previous Close:
$0.5617
Open:
$0.569
24h Volume:
804.92K
Relative Volume:
0.52
Market Cap:
$26.25M
Revenue:
-
Net Income/Loss:
$-37.65M
P/E Ratio:
-0.3374
EPS:
-1.67
Net Cash Flow:
$-24.14M
1W Performance:
-48.30%
1M Performance:
-55.98%
6M Performance:
-53.81%
1Y Performance:
-84.60%
1-Day Range:
$0.531
$0.59
1-Week Range:
$0.495
$1.09
52-Week Range:
$0.495
$4.28
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc
Sector
Industry
Phone
(408) 501-8881
Address
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.5635 | 26.25M | 0 | -37.65M | -24.14M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-23 | Initiated | ROTH MKM | Buy |
| Jun-08-23 | Initiated | The Benchmark Company | Speculative Buy |
| Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News
Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World
Reviva Pharmaceuticals Reports 2024 Financial Results - TipRanks
RVPH stock touches 52-week low at $0.6 amid market challenges - Investing.com
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Reviva Pharmaceuticals Delays Annual Report Filing - TipRanks
Reviva Pharmaceuticals Holdings Files For Non-Timely 10-KSEC Filing - MarketScreener
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Breakthrough: Reviva's Schizophrenia Treatment Delivers Powerful 1-Year Results, Losses Narrow - Stock Titan
Reviva to Present Brilaroxazine Topline Data for Long-Term - GlobeNewswire
Major Clinical Data: 52-Week Results for New Schizophrenia Drug Coming at SIRS 2025 - Stock Titan
Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 3.5% – What’s Next? - Defense World
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals adjusts executive pay, grants stock options By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals adjusts executive pay, grants stock options - Investing.com India
Reviva Pharmaceuticals Approves Executive Compensation Changes - TipRanks
Unusually active option classes on open February 12th - TipRanks
Get in on Reviva Pharmaceuticals Holdings Inc’s (RVPH) buy-in window today! - SETE News
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40 - MarketBeat
Adversity is less terrifying than hope: Reviva Pharmaceuticals Holdings Inc (RVPH) - SETE News
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts - Defense World
How should investors view Reviva Pharmaceuticals Holdings Inc (RVPH)? - US Post News
Reviva Pharmaceuticals Holdings Inc (RVPH) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Reviva Pharmaceuticals to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Reviva CEO to Showcase CNS Pipeline at Major Healthcare Conference - StockTitan
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Significant Decline in Short Interest - MarketBeat
Reviva to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Reviva to Participate in the 2025 BIO CEO & Investor Conference -January 30, 2025 at 08:01 am EST - Marketscreener.com
Reviva CEO Reveals Next-Gen Mental Health Drug Strategy at Major Biotech Summit - StockTitan
Is Reviva Pharmaceuticals Holdings Inc (RVPH) positioned for future growth? - SETE News
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
HC Wainwright Has Positive Outlook for RVPH FY2024 Earnings - Defense World
HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
HC Wainwright Issues Pessimistic Forecast for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Buy” Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Unusual Options Activity - Benzinga
Stock Traders Purchase Large Volume of Reviva Pharmaceuticals Call Options (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Given Buy Rating at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 35.9% in December - MarketBeat
Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.25 - Defense World
Geode Capital Management LLC Buys 42,376 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals stock rated buy by Roth/MKM, backed by Phase 3 results - Investing.com Nigeria
Roth Mkm Begins Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World
Maxim Group raises Reviva stock to Buy, sets new target By Investing.com - Investing.com Australia
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $11.25 - MarketBeat
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):